Method of treating myofascial pain syndrome with relaxin

• US 5,863,552 A
• Filed: 01/09/1998
• Issued: 01/26/1999
• Est. Priority Date: 11/17/1995
• Status: Expired due to Fees

• Current Assignee: SKY Bioheath Solutions, Inc.
• Original Assignee: Samuel K. Yue
• Inventors: Yue, Samuel K.
• Primary Examiner(s): Azpuru, Carlos A.
• Application Number:
  US09/005,383
• Time in Patent Office: 382 Days
• Field of Search: 424/423, 424/443, 424/449, 424/451, 424/464, 514/12, 530/324
• US Class Current: 424/423
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/2221 Relaxins

Abstract

A method of treating involuntary muscle dysfunctions includes administering a therapeuticaly effective amount of relaxin to a patient. Involuntary muscle dysfunctions amenable to treatment with relaxin include fibromyalgia, myofascial pain syndrome, chronic fatigue syndrome, dystonia, pelvic floor dysfunction, irritable bowel syndrome, and others.

Claims

1. A method for treating myofascial pain syndrome by administering to a patient exhibiting painful contraction of muscles from myofascial pain syndrome a therapeutically effective amount of relaxin hormone, thereby decreasing the amount of painful contraction of the muscles affected by relaxin.

2. The method of claim 1 wherein the step of administration comprises oral administration.

3. The method of claim 1 wherein the step of administration comprises administration by injection.

4. The method of claim 3 wherein the injection is delivered in a regional muscle area exhibiting pain.

5. The method of claim 4 wherein the injection is delivered in a select muscle of the regional muscle area exhibiting pain.

6. The method of claim 1 wherein the step of administration comprises a combination of at least two methods selected from the group consisting of topical, injection and oral methods.

7. The method of claim 1 wherein the step of administration comprises administrations transdermally through skin patches.

8. The method of claim 1 wherein the step of administration comprises administration transdermally.

9. The method of claim 1 wherein the method of administering the relaxin hormone is by subcutaneous injection of a liquid pharmaceutical formulation comprising a therapeutically effective amount of human relaxin.

10. A method of treating myofascial pain syndrome by concomitantly administering to a patient exhibiting painful contraction of muscles from involuntary muscle dysfunction of a therapeutically effective amount of:

(1) relaxin hormone; and

(2) at least one of estrogen and progesterone, thereby decreasing the amount of painful contraction of muscles affected by relaxin.

11. A method of treating myofascial pain syndrome in a patient exhibiting painful contraction of muscles from myofascial pain syndrome, the method consisting of administering a therapeutically effective amount of relaxin, selected from the group consisting of natural human relaxin, synthetic human relaxin, and animal relaxin, thereby decreasing the amount of contraction of the muscles affected by relaxin.